Results 281 to 290 of about 719,747 (310)
Some of the next articles are maybe not open access.
TGF-β1 and fibroblast growth factor-1 modify fibroblast growth factor-2 production in type II cells
American Journal of Physiology-Lung Cellular and Molecular Physiology, 2000Fibroblast growth factor (FGF)-2, which stimulates DNA synthesis by type II cells in the lung, has been shown to be regulated by transforming growth factor (TGF)-β1, an important inflammatory cytokine, in vascular epithelium. The goal of this study was to determine if FGF-2 production by alveolar type II cells is modulated by TGF-β1 or FGF-1, which ...
Ines Pagan +4 more
openaire +3 more sources
Arthritis & Rheumatism, 2009
OBJECTIVE We have previously identified in articular cartilage an abundant pool of the heparin-binding growth factor, fibroblast growth factor 2 (FGF-2), which is bound to the pericellular matrix heparan sulfate proteoglycan, perlecan. This pool of FGF-2
S. Chia +6 more
semanticscholar +1 more source
OBJECTIVE We have previously identified in articular cartilage an abundant pool of the heparin-binding growth factor, fibroblast growth factor 2 (FGF-2), which is bound to the pericellular matrix heparan sulfate proteoglycan, perlecan. This pool of FGF-2
S. Chia +6 more
semanticscholar +1 more source
Plastic and Reconstructive Surgery, 1998
Craniosynostosis is a common disorder with an unknown etiology. Recent genetic mapping studies have demonstrated a strong linkage between several familial craniosynostotic syndromes and mutations in fibroblast growth factor receptor 1 (FGF-R1) and 2 (FGF-R2).
Michael T. Longaker +4 more
openaire +3 more sources
Craniosynostosis is a common disorder with an unknown etiology. Recent genetic mapping studies have demonstrated a strong linkage between several familial craniosynostotic syndromes and mutations in fibroblast growth factor receptor 1 (FGF-R1) and 2 (FGF-R2).
Michael T. Longaker +4 more
openaire +3 more sources
Journal of Cellular Biochemistry, 2007
AbstractProgress in FGF‐2 gene therapy has been hampered by the difficulty in achieving therapeutic levels of FGF‐2 secretion. This study tested whether the addition of BMP2/4 hybrid secretion signal to the FGF‐2 gene and mutation of cys‐70 and cys‐88 to serine and asparagine, respectively, would increase the stability and secretion of active FGF‐2 ...
Sonia Kapur +4 more
openaire +3 more sources
AbstractProgress in FGF‐2 gene therapy has been hampered by the difficulty in achieving therapeutic levels of FGF‐2 secretion. This study tested whether the addition of BMP2/4 hybrid secretion signal to the FGF‐2 gene and mutation of cys‐70 and cys‐88 to serine and asparagine, respectively, would increase the stability and secretion of active FGF‐2 ...
Sonia Kapur +4 more
openaire +3 more sources
, 2006 Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020Vaibhav G Patel +2 more
exaly
Current treatment and recent progress in gastric cancer
Ca-A Cancer Journal for Clinicians, 2021Smita S Joshi, Brian D Badgwell
exaly